Conventional chemotherapy, particularly pemetrexed/platinum-based first-line therapy, may be considered as an important treatment of choice for patients unable to receive the combination of dabrafenib and trametinib yet harboring metastatic BRAF V600E-mutated lung ADC. This evidence concerns the gene BRAF and medical procedure.